활성화 응고 시간(ACT) 검사 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 검사 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Activated Clotting Time Testing Market Summary

The global activated clotting time testing market size was estimated at USD 1.19 billion in 2025 and is projected to reach USD 2.13 billion by 2033, growing at a CAGR of 7.6% from 2026 to 2033. The growth of the market is driven by the increasing cardiovascular disease prevalence, growing adoption of point of care diagnostics, and a steady increase in the number of surgical procedures particularly minimally invasive surgeries.

In addition, the expanding use of dialysis and extracorporeal membrane oxygenation (ECMO) procedures is contributing to sustained market demand. Activated Clotting Time (ACT) testing is extensively used across hospitals, cardiac catheterization laboratories, and critical care units to enable real-time monitoring of anticoagulation during complex procedures. Clinical data suggests that ACT tests are frequently performed in operating rooms during cardiac surgeries (32.4%) and cardiac catheterization procedures (32.3%), highlighting its strong and widespread clinical adoption.

The rising global burden of cardiovascular diseases, including coronary artery disease, myocardial infarction, and thrombosis, is a key driver of growth in the ACT testing market. These conditions frequently require surgical and interventional procedures such as cardiac catheterization, angioplasty, and cardiopulmonary bypass, where effective anticoagulation management is critical. During these procedures, patients are administered high doses of anticoagulants, particularly heparin, to prevent thrombus formation within blood vessels and medical devices. However, maintaining the optimal balance of anticoagulation is essential, as excessive dosing can lead to severe bleeding complications. As a result, ACT testing is widely utilized to provide a rapid, real-time assessment of clotting time, enabling clinicians to monitor and adjust anticoagulation therapy effectively.

With the increasing prevalence of cardiovascular diseases globally, there has been a corresponding rise in the volume of cardiac surgeries and interventional procedures. This trend is directly driving demand for ACT testing devices and consumables across hospitals and cardiac catheterization laboratories. For instance, according to the World Health Organization (WHO), global cardiovascular disease cases increased from approximately 311 million in 1990 to around 626 million in 2023, resulting in nearly 19.8 million deaths annually. This increasing disease burden continues to strengthen the need for reliable anticoagulation monitoring solutions, thereby supporting sustained growth in the ACT testing market.

The growing adoption of point-of-care (POC) diagnostics is a key factor driving the market, as it enables rapid bedside testing and faster clinical decision-making. POC ACT testing allows real-time monitoring of anticoagulation during procedures such as surgeries, dialysis, and ECMO, enabling clinicians promptly adjust anticoagulant dosing and reduce the risk of bleeding or clotting complications. Its ability to improve workflow efficiency, minimize sample transport, and support minimally invasive procedures has further accelerated its use. As healthcare systems increasingly shift toward decentralized diagnostics, demand for portable and automated ACT testing devices continues to rise, supported by the growing adoption of advanced systems such as the i-STAT platform in operating room settings.

Global Activated Clotting Time Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global activated clotting time testing market report on the basis of product, test type, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• ACT Analyzers
• Consumables (Cartridges, Tubes, Reagents)
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• High-Range ACT Tests
• Low-Range ACT Tests
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Surgery
• Interventional Cardiology
• Extracorporeal Membrane Oxygenation (ECMO)
• Hemodialysis
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital
• Ambulatory Surgical Centers
• Clinical Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Test Type
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Activated Clotting Time Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing cardiovascular disease prevalence
    • 3.2.1.2. Technological advancement and growing adoption of point of care diagnostics
    • 3.2.1.3. Increasing number of surgical procedures
    • 3.2.1.4. Expansion of dialysis and ECMO procedures
    • 3.2.1.5. Growth in minimally invasive surgeries
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost
    • 3.2.2.2. Shortage of skilled professionals
• 3.3. Activated Clotting Time Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Activated Clotting Time Testing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Activated Clotting Time Testing Market: Product Movement Analysis
• 4.3. Activated Clotting Time Testing Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. ACT Analyzers
  • 4.5.1. ACT Analyzers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Consumables (Cartridges, Tubes, Reagents)
  • 4.6.1. Consumables (Cartridges, Tubes, Reagents) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Activated Clotting Time Testing Market: Test Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Activated Clotting Time Testing Market: Test Type Movement Analysis
• 5.3. Activated Clotting Time Testing Market by Test Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. High-Range ACT Tests
  • 5.5.1. High-Range ACT Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Low-Range ACT Tests
  • 5.6.1. Low-Range ACT Tests Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Activated Clotting Time Testing Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Activated Clotting Time Testing Market: Application Movement Analysis
• 6.3. Activated Clotting Time Testing Market by Application Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Cardiovascular Surgery
  • 6.5.1. Cardiovascular Surgery Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Interventional Cardiology
  • 6.6.1. Interventional Cardiology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Extracorporeal Membrane Oxygenation (ECMO)
  • 6.7.1. Extracorporeal Membrane Oxygenation (ECMO) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Hemodialysis
  • 6.8.1. Hemodialysis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Activated Clotting Time Testing Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Activated Clotting Time Testing Market: End Use Movement Analysis
• 7.3. Activated Clotting Time Testing Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Hospitals
  • 7.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Ambulatory Surgical Centers
  • 7.6.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Clinical Laboratories
  • 7.7.1. Clinical Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Activated Clotting Time Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.9. Rest of Europe
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Rest of Europe market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Rest of Asia Pacific
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Rest of Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Rest of Latin America
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.5. Rest of MEA
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Rest of MEA market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2025
• 9.4. Key Company Profiles
  • 9.4.1. Werfen
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Medtronic
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Helena Laboratories Corporation
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Abbott
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Sienco, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. F. Hoffmann-La Roche Ltd
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Sysmex Corporation
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Danaher Corporation
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Thermo Fisher Scientific Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Siemens Healthineers AG., Ltd.
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. SEKISUI Diagnostics
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives